Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Furst

Showing results (41-50 of 755) with videos related to

Pageof 76
Sort By:
Seminars in Arthritis and Rheumatism|June 1, 1994
Should methotrexate be used to treat early rheumatoid arthritis?D E Furst
The Journal of Rheumatology|September 1, 2004
Window of opportunityDaniel E Furst
Rheumatology (Oxford, England)|September 17, 2008
Outcome measures in rheumatologic clinical trials and systemic sclerosisD E Furst
Nature Clinical Practice. Rheumatology|February 5, 2009
Certolizumab pegol--what role does this new TNF inhibitor have in the treatment of RA?Daniel E Furst
Bailliere'S Clinical Rheumatology|November 1, 1995
Innovative treatment approaches for rheumatoid arthritis. Cyclosporin, leflunomide and nitrogen mustardD E Furst
Postgraduate Medicine|February 15, 1990
Rheumatoid arthritis. Practical use of medicationsD E Furst
Agents and Actions. Supplements|January 1, 1985
Synovial fluid kinetics of non-steroidal anti-inflammatory drugsD E Furst
Bailliere'S Clinical Rheumatology|August 1, 1988
The basis for variability of response to anti-rheumatic drugsD E Furst
Arthritis and Rheumatism|June 4, 2005
Measuring the impact of managed care plans on the use of biologicsDaniel E Furst
Rheumatology (Oxford, England)|January 26, 2000
Leflunomide, mycophenolic acid and matrix metalloproteinase inhibitorsD E Furst
Pageof 76

Showing results (41-50 of 755) with videos related to

Sort By:
Pageof 76
Seminars in Arthritis and Rheumatism|June 1, 1994
Should methotrexate be used to treat early rheumatoid arthritis?D E Furst
The Journal of Rheumatology|September 1, 2004
Window of opportunityDaniel E Furst
Rheumatology (Oxford, England)|September 17, 2008
Outcome measures in rheumatologic clinical trials and systemic sclerosisD E Furst
Nature Clinical Practice. Rheumatology|February 5, 2009
Certolizumab pegol--what role does this new TNF inhibitor have in the treatment of RA?Daniel E Furst
Bailliere'S Clinical Rheumatology|November 1, 1995
Innovative treatment approaches for rheumatoid arthritis. Cyclosporin, leflunomide and nitrogen mustardD E Furst
Postgraduate Medicine|February 15, 1990
Rheumatoid arthritis. Practical use of medicationsD E Furst
Agents and Actions. Supplements|January 1, 1985
Synovial fluid kinetics of non-steroidal anti-inflammatory drugsD E Furst
Bailliere'S Clinical Rheumatology|August 1, 1988
The basis for variability of response to anti-rheumatic drugsD E Furst
Arthritis and Rheumatism|June 4, 2005
Measuring the impact of managed care plans on the use of biologicsDaniel E Furst
Rheumatology (Oxford, England)|January 26, 2000
Leflunomide, mycophenolic acid and matrix metalloproteinase inhibitorsD E Furst
Pageof 76